Peng Men

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9302306/publications.pdf

Version: 2024-02-01

1040056 940533 23 293 9 16 citations h-index g-index papers 23 23 23 495 all docs docs citations times ranked citing authors

#	Article	lF	CITATIONS
1	A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020). Frontiers in Pharmacology, 2022, 13, 845689.	3.5	7
2	Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China. Journal of Comparative Effectiveness Research, 2021, 10, 469-480.	1.4	5
3	Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles. Frontiers in Public Health, 2021, 9, 660514.	2.7	6
4	Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Effectiveness and Resource Allocation, 2021, 19, 46.	1.5	7
5	A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?. Hepatology International, 2021, 15, 1356-1375.	4.2	8
6	Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 696201.	3 . 5	13
7	Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. Current Medical Research and Opinion, 2020, 36, 213-217.	1.9	O
8	Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network metaâ€analysis and costâ€effectiveness analysis. Diabetes, Obesity and Metabolism, 2020, 22, 107-115.	4.4	11
9	Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1134-1142.	1.5	4
10	Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 2823-2831.	2.4	10
11	Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting. Medicine (United States), 2020, 99, e21559.	1.0	7
12	Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost–Utility Analysis. Diabetes Therapy, 2020, 11, 1745-1755.	2.5	4
13	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 197.	2.8	9
14	Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 313-320.	1.4	1
15	Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 774.	2.8	5
16	Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids in Health and Disease, 2019, 18, 144.	3.0	13
17	Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. BMC Psychiatry, 2018, 18, 286.	2.6	10
18	Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0197321.	2.5	20

PENG MEN

#	Article	IF	CITATION
19	Efficacy and Safety of Lomitapide in Hypercholesterolemia. American Journal of Cardiovascular Drugs, 2017, 17, 299-309.	2.2	24
20	Association between the AUCO-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0146224.	2.5	92
21	Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids in Health and Disease, 2016, 15, 204.	3.0	22
22	Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 6173-6184.	3.0	12
23	Design, Synthesis, and Biological Evaluation of Novel Dual Inhibitors of Secretory Phospholipase A2 and Sphingomyelin Synthase. Chinese Journal of Chemistry, 2013, 31, 1164-1170.	4.9	3